HEADER HYDROLASE 11-JAN-06 2FND TITLE HIV-1 PROTEASE COMPLEXED WITH ATAZANAVIR, AN ANTIRETROVIRAL TITLE 2 DRUG. COMPND MOL_ID: 1; COMPND 2 MOLECULE: GAG-POL POLYPROTEIN; COMPND 3 CHAIN: P; COMPND 4 FRAGMENT: HIV 1 PROTEASE; COMPND 5 EC: 3.4.23.16; COMPND 6 MUTATION: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HUMAN IMMUNODEFICIENCY VIRUS TYPE 1; SOURCE 3 STRAIN: HIV; SOURCE 4 OTHER_DETAILS: HIV KEYWDS PROTEASE WITH ATAZANAVIR EXPDTA THEORETICAL MODEL AUTHOR L.T.SENTHILKUMAR REVDAT 1 22-AUG-06 2FND 0 JRNL AUTH LAK T.SENTHILKUMAR REMARK 1 REMARK 2 REMARK 2 RESOLUTION. NOT APPLICABLE. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : NULL REMARK 3 AUTHORS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: DOCKING THE DRUG, ATAZANAVIR WITH REMARK 3 HIV1 PROTEASE USING THE TOOL HEX REMARK 4 REMARK 4 2FND COMPLIES WITH FORMAT V. 2.3, 09-JULY-1998 REMARK 5 REMARK 5 ENERGY -1.718545E+002, RMS -1.00 REMARK 6 REMARK 6 SYMMETRY TYPE: DEFAULT REMARK 7 REMARK 7 SYMMETRY MATRIX: 0 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 12-APR-2006. REMARK 100 THE RCSB ID CODE IS RCSB036081. REMARK 220 REMARK 220 EXPERIMENTAL DETAILS REMARK 220 EXPERIMENT TYPE : THEORETICAL MODELLING REMARK 220 REMARK 220 REMARK: COMPLEX STRUCTURE OF PROTEASE WITH ANTIRETROVIRAL DRUG REMARK 220 ATAZANAVIR WHICH BELONGS TO THE CLASS OF PROTEASE REMARK 220 INHIBITORS. REMARK 225 REMARK 225 THEORETICAL MODEL REMARK 225 THE COORDINATES IN THIS ENTRY REPRESENT A MODEL STRUCTURE. REMARK 225 PROTEIN DATA BANK CONVENTIONS REQUIRE THAT CRYST1 AND REMARK 225 SCALE RECORDS BE INCLUDED, BUT THE VALUES ON THESE REMARK 225 RECORDS ARE MEANINGLESS. REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS(M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 ARG P 41 CG CD NE CZ NH1 NH2 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND LENGTHS REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,2(A3,1X,A1,I4,A1,1X,A4,3X),F6.3) REMARK 500 REMARK 500 EXPECTED VALUES: ENGH AND HUBER, 1991 REMARK 500 REMARK 500 M RES CSSEQI ATM1 RES CSSEQI ATM2 DEVIATION REMARK 500 MET P 46 SD MET P 46 CE 0.044 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES: ENGH AND HUBER, 1991 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 THR P 31 N - CA - C ANGL. DEV. = -8.6 DEGREES REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1A9M RELATED DB: PDB REMARK 900 G48H MUTANT OF HIV-1 PROTEASE IN COMPLEX WITH A PEPTIDIC REMARK 900 INHIBITOR U-89360E DBREF 2FND P 1 99 UNP P03367 POL_HV1BR 500 598 SEQADV 2FND LYS P 7 UNP P03367 GLN 506 ENGINEERED SEQADV 2FND ILE P 33 UNP P03367 LEU 532 ENGINEERED SEQADV 2FND ILE P 63 UNP P03367 LEU 562 ENGINEERED SEQRES 1 P 99 PRO GLN ILE THR LEU TRP LYS ARG PRO LEU VAL THR ILE SEQRES 2 P 99 LYS ILE GLY GLY GLN LEU LYS GLU ALA LEU LEU ASP THR SEQRES 3 P 99 GLY ALA ASP ASP THR VAL ILE GLU GLU MET SER LEU PRO SEQRES 4 P 99 GLY ARG TRP LYS PRO LYS MET ILE GLY GLY ILE GLY GLY SEQRES 5 P 99 PHE ILE LYS VAL ARG GLN TYR ASP GLN ILE ILE ILE GLU SEQRES 6 P 99 ILE CYS GLY HIS LYS ALA ILE GLY THR VAL LEU VAL GLY SEQRES 7 P 99 PRO THR PRO VAL ASN ILE ILE GLY ARG ASN LEU LEU THR SEQRES 8 P 99 GLN ILE GLY CYS THR LEU ASN PHE HET DR7 1 103 HETNAM DR7 (3S,8S,9S,12S)-3,12-BIS(1,1-DIMETHYLETHYL)-8-HYDROXY- HETNAM 2 DR7 4,11-DIOXO-9-(PHENYLMETHYL)-6-[[4-(2-PYRIDINYL) HETNAM 3 DR7 PHENYL]METHYL]-2,5,6,10,13-PENTAAZATETRADECANEDIOIC HETNAM 4 DR7 ACID DIMETHYL ESTER HETSYN DR7 ATAZANAVIR; METHYL [(1S,4S,5S,10S)-4-BENZYL-1,10-DI- HETSYN 2 DR7 TERT-BUTYL-5-HYDROXY-2,9,12-TRIOXO-7-(4-PYRIDIN-2- HETSYN 3 DR7 YLBENZYL)-13-OXA-3,7,8,11-TETRAAZATETRADEC-1- HETSYN 4 DR7 YL]CARBAMATE FORMUL 2 DR7 C38 H52 N6 O7 HELIX 1 1 GLY P 86 THR P 91 1 6 SHEET 1 A 8 LYS P 43 GLY P 49 0 SHEET 2 A 8 GLY P 52 ILE P 66 -1 O VAL P 56 N LYS P 45 SHEET 3 A 8 HIS P 69 GLY P 78 -1 O GLY P 73 N ILE P 62 SHEET 4 A 8 VAL P 32 GLU P 34 1 N ILE P 33 O LEU P 76 SHEET 5 A 8 ILE P 84 ILE P 85 -1 O ILE P 84 N VAL P 32 SHEET 6 A 8 GLN P 18 LEU P 24 1 N LEU P 23 O ILE P 85 SHEET 7 A 8 LEU P 10 ILE P 15 -1 N ILE P 13 O LYS P 20 SHEET 8 A 8 GLY P 52 ILE P 66 -1 O GLU P 65 N LYS P 14 CRYST1 1.000 1.000 1.000 90.00 90.00 90.00 P 1 1 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 1.000000 0.000000 0.000000 0.00000 SCALE2 0.000000 1.000000 0.000000 0.00000 SCALE3 0.000000 0.000000 1.000000 0.00000 MASTER 77 0 1 1 8 0 0 6 0 0 0 8 END